Abstract: Inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, are chronic nonspecific inflammatory diseases of bowels whose etiology is not clear. Anti-tumor necrosis factor(TNF)-α monoclonal antibody is one of the representative biological agents used for the treatment of Crohn's disease. The "2017 revised Consensus on the Anti-TNF-α Monoclonal Antibody Therapy of Inflammatory Bowel Disease" will be published in current issue. From reviewing the new consensus, the author discussed some key points of anti-TNF-α monoclonal antibody therapy in Crohn's disease, hoping to improve clinical practice of anti-TNF-α monoclonal antibody therapy in Crohn's disease.